Posted by Michael Wonder on 01 Feb 2024
Eisai submits new drug application for mecobalamin ultra high dose formulation in Japan for the indication of amyotrophic lateral sclerosis
26 January 2024 - Eisai announced today that it has submitted a new drug application for ultra high dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis to the Pharmaceuticals and Medical Devices Agency in Japan.
In May 2022, ultrahigh-dose mecobalamin received orphan drug designation by the Ministry of Health, Labour and Welfare.
